Lymphoma & CLL Trials

Loncastuximab tesirine granted orphan drug designation in the European Union for the treatment of patients with DLBCL

On September 13, 2021, the European Commission (EC) granted orphan drug...

Satellite Symposium | Sequencing treatment options in primary refractory DLBCL

The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a...

How do we select a patient with R/R DLBCL for CAR-T?

During the European School of Haematology (ESH) How I manage CAR-T Therapies and Bispecific Antibodies for my Patients conference, the Lymphoma Hub...

ZUMA-1 4-year follow-up: Polyclonal B-cell recovery and survival outcomes with axi-cel in R/R large B-cell lymphoma

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen...

Zanubrutinib granted accelerated approval by the FDA for the treatment of patients with R/R MZL

On September 15, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to...

Zanubrutinib granted priority review by the FDA for the treatment of adult patients with R/R MZL

On May 19, 2021, the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug...

What predicts disease progression on venetoclax?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Constantine Tam, Peter MacCallum Cancer...

5-year results of the MURANO phase III trial of venetoclax + rituximab vs bendamustine + rituximab in patients with CLL

During the 62nd American Society of Hematology (ASH) Annual Meeting and...